Loading organizations...
§ Venture Capital · Suzhou, Jiangsu, China
Private investment platform engaging in direct investments and fund management, focused on the biotechnology and health sectors.
Kington Capital is a private investment platform based in Suzhou, China, specializing in direct investments and comprehensive fund management services. The firm strategically allocates capital across the biotechnology and health sectors, identifying and supporting companies within these critical industries. Its operational framework encompasses both direct equity investments into early-stage and mature ventures, alongside the management of dedicated investment funds for institutional and private clients seeking exposure to specialized markets. This dual strategy enables Kington Capital to participate in the strategic development and scaling of its portfolio companies, while also providing structured avenues for capital deployment. The platform's focused approach on life sciences and healthcare reflects an emphasis on supporting advancements in critical areas, aiming to generate returns through targeted sector expertise and market understanding. Kington Capital was established on December 31, 2015.
Kington Capital has 3 tracked investments across 3 companies. The latest tracked deal is $26.0M Series B Extension in Ronovo Surgical in January 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2020 | Ronovo Surgical | $26.0M Series B Extension | LIN Xianghong | GGV Capital, Lilly Asia Ventures, LongRiver Investments, Matrix Partners China, Vivo Capital |
| Feb 25, 2019 | Gracell Biotechnologies | $85.0M Series B | Temasek | Chengdu Miaoji, King Star Capital, Lilly Asia Ventures |
| Nov 26, 2018 | Kanova | $16.6M Series A | — | BioVenture, Northern Light Venture Capital |